The present invention is directed to pharmaceutical compositions comprising an antibody specif ic for CSl (CD2 subset 1 ), a member of the CD2 family of cell surface glycoproteins, which is highly expressed in myeloma cells, in combination with one or more therapeutic agents. Methods of treating multiple myeloma using said compositions are also the obj ect of the present invention.